It is very uncertain whether aspirin plus antipsychotics changes leaving the study early: short‐term – for any reason compared with placebo plus antipsychotics (very low certainty).
It is very uncertain whether VALPROATE + ANTIPSYCHOTICS changes leaving the study early: Acceptability of treatment Leaving the… compared with ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone (very low certainty).
It is very uncertain whether adjunctive carbamazepine + antipsychotics changes acceptability of treatment Leaving the study early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).
It is very uncertain whether ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS changes leaving the study early due to any reason (overall acceptability of… compared with PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS (very low certainty).
It is very uncertain whether summary of findings table ‐ CBT without antipsychotics changes leaving the study early ‐ for any reason ‐ overall acceptability… compared with CBT plus antipsychotics (very low certainty).
It is very uncertain whether summary of findings table ‐ CBT without antipsychotics changes leaving the study early ‐ for any reason ‐ overall acceptability… compared with antipsychotics (very low certainty).
Summary of findings table ‐ CBT without antipsychotics showed no clear difference in leaving the study early ‐ for any reason ‐ overall acceptability… compared with no specific treatment (low certainty).
Haloperidol showed no clear difference in leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (low certainty).
It is very uncertain whether haloperidol changes leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (very low certainty).
Quetiapine showed no clear difference in leaving the study early due to any reason compared with typical antipsychotics (moderate certainty).
RISPERIDONE showed no clear difference in leaving the study early: any reason compared with PERHENAZINE ‒ long‐term data (low certainty).
RISPERIDONE showed no clear difference in leaving the study early: any reason compared with ZIPRASIDONE ‒ long‐term data (> 12 months) (low certainty).
RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ long term compared with GENERAL ORAL ANTIPSYCHOTICS (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ any reason compared with typical antipsychotics (moderate certainty).
It is very uncertain whether RISPERIDONE changes leaving the study early ‒ any reason compared with CLOZAPINE ‐ all data short term (very low certainty).
It is very uncertain whether COMPARISON 1. ARIPIPRAZOLE changes leaving the study early ‐ Any reason compared with CLOZAPINE (very low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with typical antipsychotics (low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with atypical antipsychotics (low certainty).
RISPERIDONE DEPOT may leads to higher leaving the study early for any reason ‐ long term compared with TYPICAL DEPOT ANTIPSYCHOTICS (low certainty).
It is very uncertain whether levomepromazine changes leaving the study early ‐ medium term ‐ any reason compared with typical antipsychotics (very low certainty).